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significant genetic modifier of BRCA penetrance for
breast, but not ovarian, cancer. Of interest, in this con-
text, are observations from animal studies in which the
Min mouse, carrying a germ-line mutation in the murine
homologue of APC, is susceptible to mammary gland
tumorigenesis, in addition to that of the gastrointestinal
tract (Bilger et al. 1996). These data also support the
concept that genetic modifiers of BRCA penetrance are
likely to exert differential effects on breast and ovarian
tumorigenesis, as was found for the effect of rareHRAS1
alleles on ovarian, but not breast, cancer risk (Phelan et
al. 1996). As for many other genetic disorders, pene-
trance of dominant cancer-susceptibility alleles is likely
to depend on complex interactions between multiple ge-
netic and environmental modifying factors; furthermore,
those genetic factors that are found to affect BRCA pen-
etrance are not likely to be generalizable to both breast
and ovarian cancer risk.
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Germ-Line NF2 Mutations and Disease Severity in
Neurofibromatosis Type 2 Patients with Retinal
Abnormalities
To the Editor:
Neurofibromatosis type 2 (NF2; MIM 101000) is a clin-
ically variable disease caused by mutations in the NF2
tumor-suppressor gene. Commonmanifestations include
nervous system tumors and ocular abnormalities such
as presenile lens opacities and retinal abnormalities
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Table 1
Identified Germ-Line NF2 Mutations and Disease Severity in NF2 Patients with Retinal Abnormalities
Patient Exon Sequence Change Codon Change Consequence
Family
History
Retinal
Hamartoma
Epiretinal
Membrane
Disease
Severity
German:
Identified mutations:
130 3 331 CrT Gln 111 to stop Nonsense Sporadic Yes Yes Severe
161 7 5 grc Splice donor site Sporadic No Yes Severe
1088 8 701 TrG 234 Leu to Arg Missense Sporadic Yes No Severe
16 11 1047-1053 del
TGAACGC Frameshift Sporadic No Yes Severe
26 14 15741 grc Splice donor site Sporadic Yes No Mild
Unidentified mutations:
1008 Sporadic Yes No Mild
1013 Sporadic Yes No Mild
1014 Familial No Yes Severe
1021 Sporadic Yes Yes Severe
U.S.:
CH101 Sporadic Yes No Severe
CH102 Familial Yes No Mild
CH103 Familial Yes No Severe
CH104 Sporadic Yes Yes Severe
CH105 Sporadic Yes No Severe
CH106 Sporadic Yes Yes Mild
CH107 Familial Yes No Mild
CH108 Sporadic Yes No Severe
CH109 Sporadic Yes Yes Severe
NOTE.—Disease severity was as defined by Parry et al. (1994): mild disease  vestibular schwannoma (VS) and !2 non-VS intracranial
tumors, or age at onset 20 years; severe disease  VS and 2 non-VS intracranial tumors, or rare spinal tumor and age at onset !20 years.
G17693 had severe disease, but the affected parent had a late age at onset. Patients 130, 161, 16, and 26: Kluwe et al. (1996, 1998); patients
1088, 1008, 1013, 1014, and 1021: Dr. Lan Kluwe (private communication); and patients CH101–CH109: Dr. Mark Borchert (private
communication).
(Evans et al. 1992; Parry et al. 1994; Ragge et al. 1995;
Mautner et al. 1996). In general, germ-line NF2 non-
sense and frameshift mutations are associated with se-
vere disease, missense mutations with mild disease, and
splice-site mutations with variable disease severity
(Kluwe et al. 1996, 1998; Parry et al. 1996; Ruttledge
et al. 1996; Evans et al. 1998). Several studies indicate
that ocular genotype-phenotype correlationsmight exist.
Four patients studied in a three-generation NF2 family
had combined pigment epithelial and retinal hamarto-
mas (CPERH) (Bouzas et al. 1992; Parry et al. 1996).
Retinal hamartomas have been found only in NF2 pa-
tients with severe disease (Parry et al. 1994, 1996). In
reviewing phenotypes of 21 NF2 families with identified
germ-line mutations, Parry et al. (1996) noted that pa-
tients with retinal abnormalities had only nonsense mu-
tations and hypothesized that this was a genotype-phe-
notype correlation. The purpose of the present studywas
to examine the relationship among the germ-line NF2
mutation type, retinal abnormalities, and disease
severity.
We studied 18 unrelated NF2 patients with retinal
abnormalities at the Allgemeines Krankenhaus Ochsen-
zoll, Hamburg (nine patients), and the House Ear In-
stitute and Children’s Hospital, Los Angeles (nine pa-
tients). All patients provided informed consent and met
the NF2 clinical diagnostic criteria (Gutmann et al.
1997). Disease severity was as defined by Parry et al.
(1994). Retinal lesions were initially classified as retinal
hamartomas, epiretinal membranes, or CPERH (Ragge
et al. 1995; Mautner et al. 1996) and then confirmed
by a second neuro-ophthalmologist who was masked as
to the original diagnosis (patient numbers 1013 and
CH102 were examined by only one neuro-ophthalmol-
ogist). For the German patients, germ-line NF2 muta-
tions were analyzed by scanning the NF2 coding region
(17 known exons and adjacent splice junctions), 60 bp
of the 5′ UTR, and 98 bp of the 3′ UTR, by using SSCP
or temperature-gradient gel electrophoresis, followed by
direct sequencing (Jacoby et al. 1994; Kluwe et al. 1996,
1998).
Ten of 18 patients had retinal hamartomas only, 3 had
epiretinal membranes only, and 5 had both retinal ha-
martomas and epiretinal membranes. No CPERHs were
found. Six of 18 patients had mild disease, including 6
(40%) of 15 with retinal hamartomas. The germ-line
mutations that were identified in five (55.6%) of nine
German patients occurred in exons 3–14 and included
nonsense, frameshift, splice donor site, andmissensemu-
tations (table 1). Retinal abnormalities were not asso-
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ciated with mutation location: in the present study and
in Parry et al. (1996), 4 (40%) of 10 index cases with
retinal abnormalities had identified mutations in exons
1–7, compared with 7 (43.8%) of 16 index caseswithout
retinal abnormalities. Of particular interest, patient
CH101 was followed up with at least semiannual neuro-
ophthalmic examinations for 13 years. By age 15 years,
he had lost all useful vision in his right eye because of
exposure keratitis and orbital meningioma. His vision
remained 20/20 in his left eye until age 22, when he
complained of difficulty in reading. His vision had de-
creased to 20/70, and fundus examination revealed a
new retinal hamartoma in the macula of the left eye.
Parry et al. (1996) hypothesized that there was a ge-
notype-phenotype correlation between nonsense muta-
tions and retinal abnormalities, because retinal abnor-
malities occurred only in nine patients from five families
with nonsense mutations. The biological basis of this
hypothesis is unclear, because both nonsense and frame-
shift mutations are predicted to truncate the NF2 pro-
tein. Because Parry et al. (1996) identified only two
frameshift mutations, but nonsense mutations are com-
mon, the association of nonsense mutations with retinal
abnormalities may have been due to chance, in a small
number of families. In the present study we found that
NF2 patients with retinal lesions had various germ-line
NF2 mutation types. Our mutation-detection efficiency
rate (55.6%) is within the range of previous studies; the
four patients with unidentified mutations may have had
mutations in the 5′ or 3′ UTRs, intronic mutations, or
large deletions.
Parry et al. (1994, 1996) found that all NF2 patients
with retinal hamartomas had severe disease, but our re-
sults do not support an exclusive association of NF2
retinal hamartomas with severe disease. Only 60% of
patients with retinal hamartomas had severe disease,
which is similar to the 50%–75% proportion noted in
other studies for patients without retinal hamartomas
(Parry et al. 1994, 1996; Ragge et al. 1995). NF2 disease
severity and retinal lesions can vary within families (Bou-
zas et al. 1992; Baser et al. 1996a; Kluwe et al. 1996;
Parry et al. 1996; Scoles et al. 1996), and phenotypic
variability between MZ twins with NF2 suggests an in-
fluence of gene-environment interactions or stochastic
processes such as the timing of the loss of the second
NF2 allele (Baser et al. 1996b).
NF2 retinal lesions are clinically variable and have
been named according to similar-appearing lesions that
include (in other conditions) retinal hamartomas, epi-
retinal membranes, and CPERH. Ragge et al. (1995)
suggested that NF2 retinal hamartomas may be useful
for presymptomatic diagnosis in at-risk children and ad-
olescents. However, patient CH101 in the present study
demonstrates that these lesions are not always present
at birth or early childhood, although this patient may
have had a subclinical hamartoma prior to detection.
Retinal hamartomas in tuberous sclerosis also occasion-
ally grow or arise later in life (Zimmer-Galler and Rob-
ertson 1995). Epiretinal membranes in children should
raise concern for NF2 (Kaye et al. 1992; Meyers et al.
1995; Ragge et al. 1995). Because epiretinal membranes
can result from numerous pathologic processes and oc-
cur idiopathically, the cell type of the thin layer of cells
associated with these membranes also varies, and it is
premature to assume that the pathologic process or cell
type in NF2 epiretinal membranes is always the same.
Lesions similar to CPERH occurred in four members of
an NF2 family (Bouzas et al. 1992), but the germ-line
mutation was one that also occurs in patients without
retinal abnormalities (1021 CrT, Arg 341 to stop) (Sainz
et al. 1995; Parry et al. 1996), which does not support
a genotype-phenotype correlation.
In summary, retinal hamartomas are not exclusively
associated with severe NF2, and neither the type nor the
location of the germ-line NF2 mutation is the sole de-
terminant of NF2 retinal abnormalities, which can be
variably expressed in NF2 families. We recommend cau-
tion in evaluating genotype-phenotype correlations for
NF2 retinal lesions, as they are clinically variable and
pathogenetically undefined conditions.
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Gaucher Disease: The N370S Mutation in Ashkenazi
Jewish and Spanish Patients has a Common Origin
and Arose Several Thousand Years Ago
To the Editor:
The identification of highly polymorphic markers, which
are widely distributed throughout the human genome,
has allowed the mapping of several disease genes. These
markers have been used to analyze the origin, in time
and place, of the most prevalent mutations for different
diseases, such as cystic fibrosis (Morral et al. 1994), idio-
pathic torsion dystonia (Risch et al. 1995), hereditary
colon cancer (Moisio et al. 1996), factor XI deficiency
(Peretz et al. 1997), and myotonic dystrophy (Tishkoff
et al. 1998). We present the analysis of the origin of
N370S, the most common Gaucher disease (GD) mu-
tation among Ashkenazi Jewish and Spanish patients.
The results show that both patient populations share the
same ancestral haplotype and that this mutation arose
several thousand years ago.
GD (MIM 230800), caused by mutations in the glu-
cocerebrosidase (GBA) gene, is the most prevalent ly-
sosomal storage disease. It is inherited as an autosomal
recessive trait, which is particularly frequent in the Ash-
kenazi Jewish population, with a disease incidence of
∼1/850 (Beutler and Grabowski 1995). It is also found
in other populations, albeit with lower frequency, with
a range of 1/40,000–1/60,000 (Grabowski 1993).
Among Ashkenazi Jewish patients with GD, ∼70% of
the alleles carry the N370S (1226ArG) mutation (Beu-
tler et al. 1992a; Horowitz et al. 1993; Sibille et al.
1993). It appears that approximately two-thirds of the
individuals homozygous for this mutation escape detec-
tion because of the very mild clinical manifestation; thus,
the N370S frequency in the Ashkenazi Jewish popula-
tion is higher, ∼90% of all GD mutations (Beutler et al.
1993; Grabowski 1997). This mutation is also frequent
